Illumina, Inc. (ILMN) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $160.30 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: sequencing revenue (92.0%).
Illumina is a global provider of sequencing and array-based solutions for genetic and genomic analysis, serving research centers, clinical labs, pharmaceutical companies, and consumer genomics firms. Sequencing represented 92% of total revenue in 2025 with ~48% from... Read more
Sell if holding. Analyst target reached at $160.30 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: sequencing revenue (92.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news boost analyst 0.80, earnings proximity 46d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Illumina, Inc.
Latest news
- NEWS Illumina Inc. (ILMN) - Q1 2026 Earnings Preview: Key Metrics, Sector Context and Investor Expectations - High Attention — Newser neutral
- NEWS Unlocking Q1 potential of Illumina (ILMN): Exploring Wall Street estimates for key metrics - MSN — MSN positive
- NEWS Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance — Yahoo Finance positive
- NEWS Illumina (ILMN) Q1 Earnings Report Preview: What To Look For - StockStory — StockStory neutral
- NEWS Illumina (ILMN) Q1 earnings report preview: What to look for - MSN — MSN neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsequencing revenue92%10-K Item 1: 'In 2025, 2024, and 2023, total sequencing revenue comprised 92%, 91%, and 91%, respectively, of total revenue'
- MEDIUMGeographicGreater China10-K Item 1A: 'Our revenue from the Greater China region, which includes China, Taiwan, and Hong Kong, was $243 million in 2025'
Material Events(8-K, last 90d)
- 2026-04-02Item 5.02LOWDirectors Frances Arnold, Robert Epstein, and Gary Guthart notified the Board of their intention to retire as directors effective May 21, 2026 (2026 annual meeting). Retirements not the result of any dispute or disagreement. Board nominated David King for election.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $160.30 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: sequencing revenue (92.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $149.70. Score 4.9/10, moderate confidence.
Take-profit target: $173.68 (+7.9% upside). Prior stop was $149.70. Stop-loss: $149.70.
Concentration risk — Product: sequencing revenue (92.0%); Analyst target reached - limited upside remaining; Weak overall score: 4.9/10.
Illumina, Inc. trades at a P/E of 29.2 (forward 27.2). TrendMatrix value score: 3.7/10. Verdict: Sell.
28 analysts cover ILMN with a consensus score of 3.8/5. Average price target: $147.
What does Illumina, Inc. do?Illumina is a global provider of sequencing and array-based solutions for genetic and genomic analysis, serving...
Illumina is a global provider of sequencing and array-based solutions for genetic and genomic analysis, serving research centers, clinical labs, pharmaceutical companies, and consumer genomics firms. Sequencing represented 92% of total revenue in 2025 with ~48% from international customers; the company had a backlog of $738M as of December 28, 2025. China regulatory inclusion on the List of Unreliable Entities has constrained instrument exports, with Greater China revenue of $243M in 2025.